unknown
Stage
1
Investors
About
UbiquiTx develops AI-driven proteome editing therapies by integrating deep learning, computational biology, and biological automation to design targeted protein degraders for regenerative medicine and treatment of diseases through precise modulation of protein interactions.
Explore UbiquiTx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.